Actelion hit with $547M judgment as insurgents rally

Just as Actelion's executive team was gearing up for a showdown on Thursday with a rebellious crew of insurgent shareholders, the company was hit with a big court judgment. A jury ruled that Asahi Kasei Pharma should get $547 million to settle its claims against Actelion in a licensing dispute that followed Actelion's $420 million buyout of CoTherix in 2007. Actelion says it may appeal. "The news is a clear negative for Actelion both sentiment-wise and fundamentally. Without the activist process we would struggle to keep the Buy rating," said Kepler Capital Markets analyst Tero Weckroth. Story

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.